Home >> Tag Archives: Dako—

Tag Archives: Dako—

Dako’s PD-L1 approved as Keytruda companion Dx

Oct. 9, 2015—The Food and Drug Administration has approved a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer is likely to respond to Merck’s newly approved anti-PD-1 therapy, pembrolizumbac, marketed as Keytruda. Dako developed the assay, PD-L1 IHC 22C3 pharmDx, in partnership with Merck. Keytruda is approved by the FDA to treat ...

Read More »

Dako and Amgen expand collaboration, 6/15

June 2015—Dako, an Agilent Technologies Company, announced a new master collaboration agreement with Amgen. The expanded collaboration will allow both companies to benefit from knowledge sharing within the field of drug-diagnostic research and development and in relation to companion diagnostic products.

Read More »

EU launch of HER2 ISH assay, 11/14

November 2014—Dako, an Agilent Technologies company, announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis. The assay will enable pathology laboratories to integrate the Dako HER2 IQFISH and IQFISH hybridization buffer into their immunohistochemistry workflow.

Read More »

Dako and Merck to collaborate, 7/14

July 2014—Dako and Merck & Co. will collaborate to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this collaboration will be evaluated as part of the clinical development program from Merck’s investigational anti-PD-1 antibody being studied for the treatment of cancer.

Read More »

Bone marrow tissue stain, 5/14

May 2014—Dako added the Jenner-Wright Giemsa stain to its Artisan Link portfolio of automated stains. The stain is designed to provide clear differentiation and detail of the hematopoietic cells in bone marrow tissue samples for the diagnosis of cancer, aplastic anemia, and myelofibrosis.

Read More »